Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 3
1971 8
1972 4
1973 4
1974 4
1975 2
1976 5
1978 3
1979 1
1981 1
1982 1
1984 1
1989 1
1991 1
1993 3
1994 2
1995 2
1996 2
1997 4
1998 7
1999 6
2000 4
2001 6
2002 6
2003 4
2004 14
2005 7
2006 12
2007 9
2008 11
2009 2
2010 11
2011 15
2012 25
2013 25
2014 18
2015 24
2016 26
2017 20
2018 21
2019 9
2020 6
2021 14
2022 19
2023 20
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Results by year

Filters applied: . Clear all
Page 1
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators. Piccini JP, et al. Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3. Lancet. 2022. PMID: 35385695 Clinical Trial.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. Rao SV, et al. Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27. Circulation. 2022. PMID: 36030390 Clinical Trial.
Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice.
Cimen I, Natarelli L, Abedi Kichi Z, Henderson JM, Farina FM, Briem E, Aslani M, Megens RTA, Jansen Y, Mann-Fallenbuchel E, Gencer S, Duchêne J, Nazari-Jahantigh M, van der Vorst EPC, Enard W, Döring Y, Schober A, Santovito D, Weber C. Cimen I, et al. Among authors: schober a. Sci Transl Med. 2023 Nov;15(720):eadf3357. doi: 10.1126/scitranslmed.adf3357. Epub 2023 Nov 1. Sci Transl Med. 2023. PMID: 37910599
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. Pfeffer MA, et al. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508. N Engl J Med. 2021. PMID: 34758252 Clinical Trial.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S; GALILEO Investigators. Dangas GD, et al. N Engl J Med. 2020 Jan 9;382(2):120-129. doi: 10.1056/NEJMoa1911425. Epub 2019 Nov 16. N Engl J Med. 2020. PMID: 31733180 Free article. Clinical Trial.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
The future of the patient-specific Body-on-a-chip.
Williamson A, Singh S, Fernekorn U, Schober A. Williamson A, et al. Among authors: schober a. Lab Chip. 2013 Sep 21;13(18):3471-80. doi: 10.1039/c3lc50237f. Lab Chip. 2013. PMID: 23685915 Review.
MicroRNA-155 and macrophages: a fatty liaison.
Hartmann P, Schober A, Weber C. Hartmann P, et al. Among authors: schober a. Cardiovasc Res. 2014 Jul 1;103(1):5-6. doi: 10.1093/cvr/cvu135. Epub 2014 Jun 6. Cardiovasc Res. 2014. PMID: 24907979 No abstract available.
Regulatory Non-coding RNAs in Atherosclerosis.
Schober A, Maleki SS, Nazari-Jahantigh M. Schober A, et al. Handb Exp Pharmacol. 2022;270:463-492. doi: 10.1007/164_2020_423. Handb Exp Pharmacol. 2022. PMID: 33454857 Review.
Regulatory Non-coding RNAs in Atherosclerosis.
Schober A, Maleki SS, Nazari-Jahantigh M. Schober A, et al. 2021 Jan 17. In: von Eckardstein A, Binder CJ, editors. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022. 2021 Jan 17. In: von Eckardstein A, Binder CJ, editors. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022. PMID: 36122128 Free Books & Documents. Review.
364 results